fda warning letters compounded semaglutide october 2025 alerts health care providers, compounders and patients of dosing errors associated with injectable products Last month, the FDA issued

However, it's important to note that semaglutide is not FDA-approved for the treatment of MASH

GLP-1 medications act like a natural gut hormone, explains Dr

Representing the leading edge of incretin pharmacology research, R (GLP 3) builds on the dual-agonist mechanism of T (GLP 2) by adding glucagon receptor activity enabling investigation into the additive metabolic effects of all three incretin axes simultaneously

2 This multifaceted mechanism of action makes semaglutide a valuable tool in the management of type 2 diabetes

This makes them a dual-action therapy targeting both metabolic and inflammatory pathways

Educational Example: How Dilution Affects Doses Imagine a 10mg vial of Retatrutide reconstituted with 1mL of bacteriostatic water